Skip to content


Verzenio, Verzenios (abemaciclib) is a small molecule pharmaceutical. Abemaciclib was first approved as Verzenio on 2017-09-28. It has been approved in Europe to treat breast neoplasms. It is known to target cyclin-dependent kinase 6 and cyclin-dependent kinase 4. Verzenio's patent is valid until 2029-12-15 (FDA).
Trade Name Verzenios
Common Name Abemaciclib
Indication breast neoplasms
Drug Class Cyclin dependent kinase inhibitors
Get full access now